Reply: Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19

被引：0
|
作者：
Lewis-Wolfson, Temeka Dawn [1 ]
Joyner, Kayla Rena [2 ,3 ]
机构：
[1] Winchester Med Ctr, Pharm Dept, Winchester, VA 22601 USA
[2] Shenandoah Univ, Bernard J Dunn Sch Pharm, Dept Pharm Practice, Winchester, VA USA
[3] Winchester Med Ctr, Trauma & Acute Care Surg, Winchester, VA USA
来源：
ANNALS OF PHARMACOTHERAPY | 2023年 / 57卷 / 09期
关键词：
D O I：
10.1177/10600280221144936
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1118 / 1119
页数：2
相关论文
共 50 条
  • [1] Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19
    Reid, Nancy Kierstin
    Joyner, Kayla Rena
    Lewis-Wolfson, Temeka Dawn
    [J]. ANNALS OF PHARMACOTHERAPY, 2023, 57 (07) : 769 - 775
  • [2] BARICITINIB VERSUS TOCILIZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE COVID-19
    Lewis-Wolfson, Temeka
    Joyner, Kayla
    Reid, Nancy
    [J]. CRITICAL CARE MEDICINE, 2023, 51 (01) : 191 - 191
  • [3] Comment: Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19
    Mungmunpuntipantip, Rujittika
    Wiwanitkit, Viroj
    [J]. ANNALS OF PHARMACOTHERAPY, 2023, 57 (09) : 1117 - 1117
  • [4] USE OF BARICITINIB AND TOCILIZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE COVID-19 IN HOSPITALIZED PATIENTS
    Xibille Friedmann, D. X.
    Carrillo Vazquez, S. M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 899 - 900
  • [5] Adverse Effects of Tocilizumab Versus Baricitinib in Severe COVID-19
    Leaf, David E.
    Gordon, Anthony C.
    Lawler, Patrick R.
    [J]. CRITICAL CARE MEDICINE, 2023, 51 (09) : E184 - E185
  • [6] Baricitinib or Tocilizumab? Treatment of Patients Hospitalized With Severe COVID-19
    Cawcutt, Kelly A.
    Kalil, Andre C.
    [J]. CRITICAL CARE MEDICINE, 2023, 51 (03) : 413 - 415
  • [7] Tocilizumab Versus Baricitinib for the Treatment of COVID-19 in Patients With Obesity
    Troyer, Bradley S.
    Scherrer, Nicole Kovacic
    Garavaglia, Jeffrey
    [J]. JOURNAL OF PHARMACY PRACTICE, 2024, 37 (03) : 632 - 636
  • [8] Outcomes and Adverse Effects of Baricitinib Versus Tocilizumab in the Management of Severe COVID-19*
    Peterson, Joy H.
    Paranjape, Neha S.
    Grundlingh, Nina
    Priestley, Jennifer L.
    [J]. CRITICAL CARE MEDICINE, 2023, 51 (03) : 337 - 346
  • [9] Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia Reply
    Berlana, David
    Cardona-Pascual, Ignacio
    Montoro-Ronsano, J. Bruno
    [J]. MEDICINA CLINICA, 2022, 159 (08): : E55 - E55
  • [10] Baricitinib for COVID-19: a suitable treatment? Reply
    Richardson, Peter J.
    Corbellino, Mario
    Stebbing, Justin
    [J]. LANCET INFECTIOUS DISEASES, 2020, 20 (09): : 1013 - 1014
12345